Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00185_DB00872_nanopub.RAJO3HiH_CbhUGVXWTtXO_78DekZZAPqIQoep6-Xln1rk#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00185_DB00872 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00185_DB00872 label "DDI between Cevimeline and Conivaptan - Conivaptan may increase the serum concentration of CYP3A4 substrates such as cevimeline. Upon completion/discontinuation of conivaptan, allow at least 7 days before initiating therapy with drugs that are CYP3A4 substrates. [drugbank_resource:DB00185_DB00872]" assertion.
- drugbank_resource:DB00185_DB00872 identifier "drugbank_resource:DB00185_DB00872" assertion.
- drugbank_resource:DB00185_DB00872 title "DDI between Cevimeline and Conivaptan - Conivaptan may increase the serum concentration of CYP3A4 substrates such as cevimeline. Upon completion/discontinuation of conivaptan, allow at least 7 days before initiating therapy with drugs that are CYP3A4 substrates." assertion.
- drugbank:DB00872 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00185_DB00872 assertion.
- drugbank:DB00185 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00185_DB00872 assertion.